Marked for death: Targeting epigenetic changes in cancer

The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data

Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455 · see citing works

Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal

Gao, J., Aksoy, B. A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S. O., Sun, Y., Jacobsen, A., Sinha, R., Larsson, E., et al. (2013) · Science Signaling · doi:10.1126/scisignal.2004088 · Cited by 15,160 · see citing works

Epigenetic Regulations of GABAergic Neurotransmission: Relevance for Neurological Disorders and Epigenetic Therapy

Shrestha, S., & Offer, S. M. (2016) · Medical Epigenetics · doi:10.1159/000444713 · Cited by 8,949 · see citing works

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

Gerlinger, M., Rowan, A. J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113205 · Cited by 7,774 · see citing works

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683 · see citing works

<i>IDH1</i> and <i>IDH2</i> Mutations in Gliomas

Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847 · see citing works

Comprehensive molecular profiling of lung adenocarcinoma

The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13385 · Cited by 5,732 · see citing works

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005) · Nature · doi:10.1038/nature03443 · Cited by 5,198 · see citing works

Selective inhibition of BET bromodomains

Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W. B., Fedorov, O., Morse, E. M., Keates, T., Hickman, T. T., Felletar, I., et al. (2010) · Nature · doi:10.1038/nature09504 · Cited by 4,262 · see citing works

The landscape of somatic copy-number alteration across human cancers

Beroukhim, R., Mermel, C. H., Porter, D., Wei, G., Raychaudhuri, S., Donovan, J., Barretina, J., Boehm, J. S., Dobson, J., Urashima, M., et al. (2010) · Nature · doi:10.1038/nature08822 · Cited by 4,017 · see citing works

Comprehensive molecular characterization of clear cell renal cell carcinoma

The Cancer Genome Atlas Research Network (2013) · Nature · doi:10.1038/nature12222 · Cited by 3,485 · see citing works

The Consensus Coding Sequences of Human Breast and Colorectal Cancers

Sjöblom, T., Jones, S., Wood, L. D., Parsons, D. W., Lin, J., Barber, T. D., Mandelker, D. L., Leary, R. J., Ptak, J., Silliman, N., et al. (2006) · Science · doi:10.1126/science.1133427 · Cited by 3,161 · see citing works

Regulation of chromatin structure by site-specific histone H3 methyltransferases

Rea, S., Eisenhaber, F., O'Carroll, D., Strahl, B. D., Sun, Z.-W., Schmid, M., Opravil, S., Mechtler, K., Ponting, C. P., Allis, C. D., et al. (2000) · Nature · doi:10.1038/35020506 · Cited by 2,845 · see citing works

A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations

Sharma, S. V., Lee, D. Y., Li, B., Quinlan, M. P., Takahashi, F., Maheswaran, S., McDermott, U., Azizian, N., Zou, L., Fischbach, M. A., et al. (2010) · Cell · doi:10.1016/j.cell.2010.02.027 · Cited by 2,770 · see citing works

Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation

Figueroa, M. E., Abdel-Wahab, O., Lu, C., Ward, P. S., Patel, J., Shih, A., Li, Y., Bhagwat, N., Vasanthakumar, A., Fernandez, H. F., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.11.015 · Cited by 2,766 · see citing works

Genome-Scale CRISPR-Mediated Control of Gene Repression and Activation

Gilbert, L. A., Horlbeck, M. A., Adamson, B., Villalta, J. E., Chen, Y., Whitehead, E. H., Guimaraes, C., Panning, B., Ploegh, H. L., Bassik, M. C., et al. (2014) · Cell · doi:10.1016/j.cell.2014.09.029 · Cited by 2,728 · see citing works

Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma

Schwartzentruber, J., Korshunov, A., Liu, X.-Y., Jones, D. T. W., Pfaff, E., Jacob, K., Sturm, D., Fontebasso, A. M., Quang, D.-A. K., Tönjes, M., et al. (2012) · Nature · doi:10.1038/nature10833 · Cited by 2,631 · see citing works

A landscape of driver mutations in melanoma

Hodis, E., Watson, I. R., Kryukov, G. V., Arold, S. T., Imielinski, M., Theurillat, J.-P., Nickerson, E., Auclair, D., Li, L., Place, C., et al. (2012) · Cell · doi:10.1016/j.cell.2012.06.024 · Cited by 2,610 · see citing works

Activation of p53 Sequence-Specific DNA Binding by Acetylation of the p53 C-Terminal Domain

Gu, W., & Roeder, R. G. (1997) · Cell · doi:10.1016/s0092-8674(00)80521-8 · Cited by 2,559 · see citing works

Cancer-epigenetics comes of age

Jones, P. A., & Laird, P. W. (1999) · Nature Genetics · doi:10.1038/5947 · Cited by 2,334 · see citing works

Recurring mutations found by sequencing an acute myeloid leukemia genome

Mardis, E. R., Ding, L., Dooling, D. J., Larson, D. E., McLellan, M. D., Chen, K., Koboldt, D. C., Fulton, R. S., Delehaunty, K. D., McGrath, S. D., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0903840 · Cited by 2,219 · see citing works

The Polycomb group protein EZH2 directly controls DNA methylation

Viré, E., Brenner, C., Deplus, R., Blanchon, L., Fraga, M., Didelot, C., Morey, L., Van Eynde, A., Bernard, D., Vanderwinden, J.-M., et al. (2006) · Nature · doi:10.1038/nature04431 · Cited by 2,204 · see citing works

A Landscape of Pharmacogenomic Interactions in Cancer

Iorio, F., Knijnenburg, T. A., Vis, D. J., Bignell, G. R., Menden, M. P., Schubert, M., Aben, N., Gonçalves, E., Barthorpe, S., Lightfoot, H., et al. (2016) · Cell · doi:10.1016/j.cell.2016.06.017 · Cited by 2,090 · see citing works

Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses

Chiappinelli, K. B., Strissel, P. L., Desrichard, A., Li, H., Henke, C., Akman, B., Hein, A., Rote, N. S., Cope, L. M., Snyder, A., et al. (2015) · Cell · doi:10.1016/j.cell.2015.07.011 · Cited by 2,022 · see citing works

IDH mutation impairs histone demethylation and results in a block to cell differentiation

Lu, C., Ward, P. S., Kapoor, G. S., Rohle, D., Turcan, S., Abdel-Wahab, O., Edwards, C. R., Khanin, R., Figueroa, M. E., Melnick, A., et al. (2012) · Nature · doi:10.1038/nature10860 · Cited by 1,985 · see citing works

<i>DNMT3A</i> Mutations in Acute Myeloid Leukemia

Ley, T. J., Ding, L., Walter, M. J., McLellan, M. D., Lamprecht, T., Larson, D. E., Kandoth, C., Payton, J. E., Baty, J., Welch, J., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1005143 · Cited by 1,983 · see citing works

IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype

Turcan, S., Rohle, D., Goenka, A., Walsh, L. A., Fang, F., Yilmaz, E., Campos, C., Fabius, A. W. M., Lu, C., Ward, P. S., et al. (2012) · Nature · doi:10.1038/nature10866 · Cited by 1,974 · see citing works

Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing

Imielinski, M., Berger, A. H., Hammerman, P. S., Hernandez, B., Pugh, T. J., Hodis, E., Cho, J., Suh, J., Capelletti, M., Sivachenko, A., et al. (2012) · Cell · doi:10.1016/j.cell.2012.08.029 · Cited by 1,789 · see citing works

EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations

McCabe, M. T., Ott, H. M., Ganji, G., Korenchuk, S., Thompson, C., Van Aller, G. S., Liu, Y., Graves, A. P., III, A. D. P., Diaz, E., et al. (2012) · Nature · doi:10.1038/nature11606 · Cited by 1,786 · see citing works

Mutation in <i>TET2</i> in Myeloid Cancers

Delhommeau, F., Dupont, S., Valle, V. D., James, C., Trannoy, S., Massé, A., Kosmider, O., Le Couedic, J.-P., Robert, F., Alberdi, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810069 · Cited by 1,776 · see citing works

Phthalimide conjugation as a strategy for in vivo target protein degradation

Winter, G. E., Buckley, D. L., Paulk, J., Roberts, J. M., Souza, A., Dhe-Paganon, S., & Bradner, J. E. (2015) · Science · doi:10.1126/science.aab1433 · Cited by 1,760 · see citing works

DAXX / ATRX , MEN1 , and mTOR Pathway Genes Are Frequently Altered in Pancreatic Neuroendocrine Tumors

Jiao, Y., Shi, C., Edil, B. H., de Wilde, R. F., Klimstra, D. S., Maitra, A., Schulick, R. D., Tang, L. H., Wolfgang, C. L., Choti, M. A., et al. (2011) · Science · doi:10.1126/science.1200609 · Cited by 1,717 · see citing works

<i>ARID1A</i> Mutations in Endometriosis-Associated Ovarian Carcinomas

Wiegand, K. C., Shah, S. P., Al-Agha, O. M., Zhao, Y., Tse, K., Zeng, T., Senz, J., McConechy, M. K., Anglesio, M. S., Kalloger, S. E., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1008433 · Cited by 1,712 · see citing works

The somatic mutation profiles of 2,433 breast cancers refine their genomic and transcriptomic landscapes

Pereira, B., Chin, S., Rueda, O. M., Vollan, H. K. M., Provenzano, E., Bardwell, H. A., Pugh, M., Jones, L. R., Russell, R., Sammut, S., et al. (2016) · Nature Communications · doi:10.1038/ncomms11479 · Cited by 1,712 · see citing works

The landscape of cancer genes and mutational processes in breast cancer

Stephens, P. J., Tarpey, P. S., Davies, H. R., Loo, P. V., Greenman, C., Wedge, D. C., Nik‐Zainal, S., Martin, S., Varela, I., Bignell, G. R., et al. (2012) · Nature · doi:10.1038/nature11017 · Cited by 1,686 · see citing works

Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin

Morin, R. D., Johnson, N. A., Severson, T., Mungall, A. J. J., An, J., Goya, R., Paul, J. E., Boyle, M., Woolcock, B. W., Kuchenbauer, F. C., et al. (2010) · Nature Genetics · doi:10.1038/ng.518 · Cited by 1,670 · see citing works

Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer

The Multiple Leiomyoma Consortium (2002) · Nature Genetics · doi:10.1038/ng849 · Cited by 1,635 · see citing works

DNA hypermethylation in tumorigenesis: epigenetics joins genetics

Baylin, S. B., & Herman, J. G. (2000) · Trends in Genetics · doi:10.1016/s0168-9525(99)01971-x · Cited by 1,615 · see citing works

Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma

Morin, R. D., Mendez-Lago, M., Mungall, A. J., Goya, R., Mungall, K. L., Corbett, R. D., Johnson, N. A., Severson, T. M., Chiu, R., Field, M., et al. (2011) · Nature · doi:10.1038/nature10351 · Cited by 1,614 · see citing works

The genetic basis of early T-cell precursor acute lymphoblastic leukaemia

Zhang, J., Ding, L., Holmfeldt, L., Wu, G., Heatley, S. L., Payne-Turner, D., Easton, J., Chen, X., Wang, J., Rusch, M., et al. (2012) · Nature · doi:10.1038/nature10725 · Cited by 1,596 · see citing works

Cancer/testis antigens, gametogenesis and cancer

Simpson, A. J. G., Caballero, O. L., Jungbluth, A. A., Chen, Y., & Old, L. J. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1669 · Cited by 1,587 · see citing works

Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer

Versteege, I., Sévenet, N., Lange, J., Rousseau-Merck, M.-F., Ambros, P. F., Handgretinger, R., Aurias, A., & Delattre, O. (1998) · Nature · doi:10.1038/28212 · Cited by 1,552 · see citing works

Histone deacetylase inhibitors: molecular mechanisms of action

Xu, W. S., Parmigiani, R. B., & Marks, P. A. (2007) · Oncogene · doi:10.1038/sj.onc.1210620 · Cited by 1,542 · see citing works

DNA-Demethylating Agents Target Colorectal Cancer Cells by Inducing Viral Mimicry by Endogenous Transcripts

Roulois, D., Loo Yau, H., Singhania, R., Wang, Y., Danesh, A., Shen, S. Y., Han, H., Liang, G., Jones, P. A., Pugh, T. J., et al. (2015) · Cell · doi:10.1016/j.cell.2015.07.056 · Cited by 1,527 · see citing works

Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia

Dawson, M. A., Prinjha, R. K., Dittmann, A., Giotopoulos, G., Bantscheff, M., Chan, W.-I., Robson, S. C., Chung, C., Hopf, C., Savitski, M. M., et al. (2011) · Nature · doi:10.1038/nature10509 · Cited by 1,512 · see citing works

Induction of tumors in mice by genomic hypomethylation

Gaudet, F., Hodgson, J. G., Eden, A., Jackson-Grusby, L., Dausman, J., Gray, J. W., Leonhardt, H., & Jaenisch, R. (2003) · Science · doi:10.1126/science.1083558 · Cited by 1,499 · see citing works

Targeting EZH2 in cancer

Kim, K. H., & Roberts, C. W. M. (2016) · Nature Medicine · doi:10.1038/nm.4036 · Cited by 1,471 · see citing works

Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma

Guichard, C., Amaddeo, G., Imbeaud, S., Ladeiro, Y., Pelletier, L., Benmaad, I., Caldéraro, J., Bioulac‐Sage, P., Letexier, M., Degos, F., et al. (2012) · Nature Genetics · doi:10.1038/ng.2256 · Cited by 1,451 · see citing works

Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancy

Kadoch, C., Hargreaves, D. C., Hodges, H. C., Elias, L., Ho, L., Ranish, J. A., & Crabtree, G. R. (2013) · Nature Genetics · doi:10.1038/ng.2628 · Cited by 1,443 · see citing works

FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma

Mann, B. S., Johnson, J. R., Cohen, M. H., Justice, R., & Pazdur, R. (2007) · The Oncologist · doi:10.1634/theoncologist.12-10-1247 · Cited by 1,365 · see citing works

Inhibition of PRC2 Activity by a Gain-of-Function H3 Mutation Found in Pediatric Glioblastoma

Lewis, P. W., Müller, M. M., Koletsky, M. S., Cordero, F., Lin, S., Banaszynski, L. A., Garcia, B. A., Muir, T. W., Becher, O. J., & Allis, C. D. (2013) · Science · doi:10.1126/science.1232245 · Cited by 1,345 · see citing works

Epigenetic protein families: a new frontier for drug discovery

Arrowsmith, C. H., Bountra, C., Fish, P. V., Lee, K., & Schapira, M. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3674 · Cited by 1,327 · see citing works

MLL translocations, histone modifications and leukaemia stem-cell development

Krivtsov, A., & Armstrong, S. (2007) · Nature Reviews. Cancer · doi:10.1038/nrc2253 · Cited by 1,294 · see citing works

Epigenetic therapy of cancer: past, present and future

Yoo, C. B., & Jones, P. A. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1930 · Cited by 1,291 · see citing works

Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma

Varela, I., Tarpey, P. S., Raine, K. M., Huang, D., Ong, C. K., Stephens, P., Davies, H. R., Jones, D., Lin, M., Teague, J. W., et al. (2011) · Nature · doi:10.1038/nature09639 · Cited by 1,278 · see citing works

A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers

Bischoff, J., Anderson, L., Zhu, Y.-F., Mossie, K., Ng, L., Souza, B., Schryver, B., Flanagan, P., Clairvoyant, F., Ginther, C., et al. (1998) · EMBO Journal · doi:10.1093/emboj/17.11.3052 · Cited by 1,271 · see citing works

DNMT1 and DNMT3b cooperate to silence genes in human cancer cells

Rhee, I. P., Bachman, K. E., Park, B. H., Jair, K.-W., Yen, R.-W. C., Schuebel, K. E., Cui, H., Feinberg, A. P., Christoph Lengauer, C., Kinzler, K. W., et al. (2002) · Nature · doi:10.1038/416552a · Cited by 1,243 · see citing works

Frequent Mutations of Chromatin Remodeling Gene ARID1A in Ovarian Clear Cell Carcinoma

Jones, S., Wang, T., Shih, I., Mao, T., Nakayama, K., Roden, R. B. S., Glas, R., Slamon, D. J., Diaz, L. A., Vogelstein, B., et al. (2010) · Science · doi:10.1126/science.1196333 · Cited by 1,218 · see citing works

The genomic complexity of primary human prostate cancer

Berger, M. F., Lawrence, M. S., Demichelis, F., Drier, Y., Cibulskis, K., Sivachenko, A., Sboner, A., Esgueva, R., Pflueger, D., Sougnez, C. L., et al. (2011) · Nature · doi:10.1038/nature09744 · Cited by 1,213 · see citing works

Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing

Gerlinger, M., Horswell, S. D., Larkin, J., Rowan, A., Salm, M., Varela, I., Fisher, R. A., McGranahan, N., Matthews, N., Santos, C. R., et al. (2014) · Nature Genetics · doi:10.1038/ng.2891 · Cited by 1,211 · see citing works

Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy

Peng, D., Kryczek, I., Nagarsheth, N., Zhao, L., Wei, S., Wang, W., Sun, Y., Zhao, E., Vatan, L., Szeliga, W., et al. (2015) · Nature · doi:10.1038/nature15520 · Cited by 1,201 · see citing works

Inhibition of α-KG-dependent histone and DNA demethylases by fumarate and succinate that are accumulated in mutations of FH and SDH tumor suppressors

Xiao, M., Yang, H., Xu, W., Ma, S., Lin, H., Zhu, H., Liu, L., Liu, Y., Yang, C., Xu, Y., et al. (2012) · Genes &amp; Development · doi:10.1101/gad.191056.112 · Cited by 1,188 · see citing works

Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes

Dalgliesh, G. L., Furge, K., Greenman, C., Chen, L., Bignell, G., Butler, A., Davies, H., Edkins, S., Hardy, C., Latimer, C., et al. (2010) · Nature · doi:10.1038/nature08672 · Cited by 1,173 · see citing works

DNA methylation and gene silencing in cancer

Baylin, S. B. (2005) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0354 · Cited by 1,156 · see citing works

Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders

Ernst, T., Chase, A. J., Score, J., Hidalgo-Curtis, C. E., Bryant, C., Jones, A. V., Waghorn, K., Zoi, K., Ross, F. M., Reiter, A., et al. (2010) · Nature Genetics · doi:10.1038/ng.621 · Cited by 1,139 · see citing works

Dna Hypomethylation In Cancer Cells

Ehrlich, M. (2009) · Epigenomics · doi:10.2217/epi.09.33 · Cited by 1,065 · see citing works

Analysis of the IDH1 codon 132 mutation in brain tumors

Balss, J., Meyer, J., Mueller, W., Korshunov, A., Hartmann, C., & von Deimling, A. (2008) · Acta Neuropathologica · doi:10.1007/s00401-008-0455-2 · Cited by 1,036 · see citing works

The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases

Chowdhury, R., Yeoh, K. K., Tian, Y., Hillringhaus, L., Bagg, E. A., Rose, N. R., Leung, I. K. H., Li, X. S., Woon, E. C. Y., Yang, M., et al. (2011) · The EMBO Reports · doi:10.1038/embor.2011.43 · Cited by 1,035 · see citing works

Histone deacetylases and cancer

Glozak, M. A., & Seto, E. (2007) · Oncogene · doi:10.1038/sj.onc.1210610 · Cited by 1,031 · see citing works

<i>IDH1</i> and <i>IDH2</i> mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours

Amary, M. F., Bacsi, K., Maggiani, F., Damato, S., Halai, D., Berisha, F., Pollock, R., O'Donnell, P., Grigoriadis, A., Diss, T., et al. (2011) · The Journal of Pathology · doi:10.1002/path.2913 · Cited by 1,023 · see citing works

brahma: A regulator of Drosophila homeotic genes structurally related to the yeast transcriptional activator SNF2SWI2

Tamkun, J. W., Deuring, R., Scott, M. P., Kissinger, M., Pattatucci, A. M. L., Kaufman, T. C., & Kennison, J. A. (1992) · Cell · doi:10.1016/0092-8674(92)90191-e · Cited by 966 · see citing works

Inactivating mutations of acetyltransferase genes in B-cell lymphoma

Pasqualucci, L., Dominguez-Sola, D., Chiarenza, A., Fabbri, G., Grunn, A., Trifonov, V., Kasper, L. H., Lerach, S., Tang, H., Ma, J., et al. (2011) · Nature · doi:10.1038/nature09730 · Cited by 949 · see citing works

Selective Killing of Mixed Lineage Leukemia Cells by a Potent Small-Molecule DOT1L Inhibitor

Daigle, S. R., Olhava, E. J., Therkelsen, C. A., Majer, C. R., Sneeringer, C. J., Song, J. J., Johnston, L. D., Scott, M. P., Smith, J. J., Xiao, Y., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.06.009 · Cited by 926 · see citing works

MLL-rearranged Leukemia is Dependent on Aberrant H3K79 Methylation by DOT1L

Bernt, K., Zhu, N., Sinha, A., Vempati, S., Faber, J., Krivtsov, A., Feng, Z.-H., Punt, N., Daigle, A., Bullinger, L., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.06.010 · Cited by 896 · see citing works

Landscape of genomic alterations in cervical carcinomas

Ojesina, A. I., Lichtenstein, L., Freeman, S. S., Pedamallu, C. S., Imaz-Rosshandler, I., Pugh, T. J., Cherniack, A. D., Ambrogio, L., Cibulskis, K., Bertelsen, B. I., et al. (2013) · Nature · doi:10.1038/nature12881 · Cited by 861 · see citing works

Reversal of H3K9me2 by a Small-Molecule Inhibitor for the G9a Histone Methyltransferase

Kubicek, S., O'Sullivan, R. J., August, E. M., Hickey, E. R., Zhang, Q., Teodoro, M. L., Rea, S., Mechtler, K., Kowalski, J. A., Homon, C. A., et al. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.01.017 · Cited by 859 · see citing works

Gene essentiality and synthetic lethality in haploid human cells

Blomen, V. A., Májek, P., Jae, L. T., Bigenzahn, J. W., Nieuwenhuis, J., Staring, J., Sacco, R., van Diemen, F. R., Olk, N., Stukalov, A., et al. (2015) · Science · doi:10.1126/science.aac7557 · Cited by 857 · see citing works

Hypomethylation of DNA from Benign and Malignant Human Colon Neoplasms

Goelz, S. E., Vogelstein, B., Hamilton, S. R., & Feinberg, A. P. (1985) · Science · doi:10.1126/science.2579435 · Cited by 841 · see citing works

Germ-line and acquired mutations of INI1 in atypical teratoid and rhabdoid tumors.

Biegel, J. A., Zhou, J. Y., RORKE, L. B., Stenstrom, C., Wainwright, L. M., & Fogelgren, B. (1999) · PubMed · Cited by 836 · see citing works

Novel mutations target distinct subgroups of medulloblastoma

Robinson, G. W., Parker, M. D., Kranenburg, T. A., Lu, C., Chen, X. '., Ding, L., Phoenix, T. N., Hedlund, E., Wei, L., Zhu, X., et al. (2012) · Nature · doi:10.1038/nature11213 · Cited by 835 · see citing works

Stabilization of Chromatin Structure by PRC1, a Polycomb Complex

Shao, Z., Raible, F., Mollaaghababa, R., Guyon, J. R., Wu, C.-T., Bender, W. W., & Kingston, R. E. (1999) · Cell · doi:10.1016/s0092-8674(00)80604-2 · Cited by 821 · see citing works

hDOT1L Links Histone Methylation to Leukemogenesis

Okada, Y., Feng, Q. F., Lin, Y.-H., Jiang, Q., Li, Y., Coffield, V. M., Su, L., Xu, G., & Zhang, Y. (2005) · Cell · doi:10.1016/j.cell.2005.02.020 · Cited by 819 · see citing works

Reduced H3K27me3 and DNA Hypomethylation Are Major Drivers of Gene Expression in K27M Mutant Pediatric High-Grade Gliomas

Bender, S., Tang, Y., Lindroth, A. M., Hovestadt, V., Jones, D. T. W., Kool, M., Zapatka, M., Northcott, P. A., Sturm, D., Wang, W., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.10.006 · Cited by 818 · see citing works

Non-coding recurrent mutations in chronic lymphocytic leukaemia

Puente, X. S., Beà, S., Valdés‐Mas, R., Villamor, N., Gutiérrez‐Abril, J., Martín-Subero, J. I., Munar, M., Rubio-Pérez, C., Jares, P., Aymerich, M., et al. (2015) · Nature · doi:10.1038/nature14666 · Cited by 813 · see citing works

Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia

Yan, X., Xu, J., Gu, Z., Pan, C., Lü, G., Shen, Y., Shi, J., Zhu, Y., Tang, L., Zhang, X., et al. (2011) · Nature Genetics · doi:10.1038/ng.788 · Cited by 806 · see citing works

Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2

Knutson, S. K., Warholic, N. M., Wigle, T. J., Klaus, C. R., Allain, C. J., Raimondi, A., Scott, M. P., Chesworth, R., Moyer, M. P., Copeland, R. A., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1303800110 · Cited by 794 · see citing works

Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer

van Haaften, G., Dalgliesh, G. L., Davies, H., Chen, L., Bignell, G., Greenman, C., Edkins, S., Hardy, C., O'Meara, S., Teague, J., et al. (2009) · Nature Genetics · doi:10.1038/ng.349 · Cited by 784 · see citing works

SDH mutations establish a hypermethylator phenotype in paraganglioma

Letouzé, E., Martinelli, C., Loriot, C., Burnichon, N., Abermil, N., Ottolenghi, C., Janin, M., Menara, M., Nguyen, A. T., Benit, P., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.04.018 · Cited by 776 · see citing works

Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer

Wang, K., Kan, J., Yuen, S. T., Shi, S. T., Chu, K., Law, S. Y.-K., Chan, T. L., Kan, Z., Chan, A. S. Y., Tsui, W. Y., et al. (2011) · Nature Genetics · doi:10.1038/ng.982 · Cited by 770 · see citing works

The translocation t(8;16)(p11;p13) of acute myeloid leukaemia fuses a putative acetyltransferase to the CREB–binding protein

Borrow, J., Stanton, V. P., Andresen, J. M., Becher, R., Behm, F. G., Chaganti, R. S. K., Civin, C. I., Distèche, C. M., Dubé, I. D., Frischauf, A. M., et al. (1996) · Nature Genetics · doi:10.1038/ng0996-33 · Cited by 766 · see citing works

Acquired mutations in TET2 are common in myelodysplastic syndromes

Langemeijer, S. M. C., Kuiper, R. P., Berends, M., Knops, R., Aslanyan, M. G., Massop, M., Stevens-Linders, E., van Hoogen, P., van Kessel, A. G., Raymakers, R. A. P., et al. (2009) · Nature Genetics · doi:10.1038/ng.391 · Cited by 755 · see citing works

Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder

Gui, Y., Guo, G., Huang, Y., Hu, X., Tang, A., Gao, S., Wu, R., Chen, C., Li, X., Zhou, L., et al. (2011) · Nature Genetics · doi:10.1038/ng.907 · Cited by 748 · see citing works

What are super-enhancers?

Pott, S., & Lieb, J. D. (2014) · Nature Genetics · doi:10.1038/ng.3167 · Cited by 745 · see citing works

Discovery of cancer drug targets by CRISPR-Cas9 screening of protein domains

Shi, J., Wang, E., Milazzo, J. P., Wang, Z., Kinney, J. B., & Vakoc, C. R. (2015) · Nature Biotechnology · doi:10.1038/nbt.3235 · Cited by 739 · see citing works

Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies

Abdel-Wahab, O., Mullally, A., Hedvat, C., Garcia-Manero, G., Patel, J., Wadleigh, M., Malinge, S., Yao, J., Kilpivaara, O., Bhat, R., et al. (2009) · Blood · doi:10.1182/blood-2009-03-210039 · Cited by 727 · see citing works

Potent inhibition of DOT1L as treatment of MLL-fusion leukemia

Daigle, S. R., Olhava, E. J., Therkelsen, C. A., Basavapathruni, A., Jin, L., Boriack-Sjodin, P. A., Allain, C. J., Klaus, C. R., Raimondi, A., Scott, M. P., et al. (2013) · Blood · doi:10.1182/blood-2013-04-497644 · Cited by 722 · see citing works

A vaccine targeting mutant IDH1 induces antitumour immunity

Schumacher, T., Bunse, L., Pusch, S., Sahm, F., Wiestler, B., Quandt, J., Menn, O., Osswald, M., Oezen, I., Ott, M., et al. (2014) · Nature · doi:10.1038/nature13387 · Cited by 707 · see citing works

The histone H3.3K27M mutation in pediatric glioma reprograms H3K27 methylation and gene expression

Chan, K.-M., Fang, D., Gan, H., Hashizume, R., Yu, C., Schroeder, M., Gupta, N., Mueller, S., James, C. D., Jenkins, R., et al. (2013) · Genes &amp; Development · doi:10.1101/gad.217778.113 · Cited by 707 · see citing works

Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents

Yang, H., Bueso-Ramos, C., DiNardo, C., Estecio, M. R., Davanlou, M., Geng, Q.-R., Fang, Z., Nguyen, M., Pierce, S., Wei, Y., et al. (2014) · Leukemia · doi:10.1038/leu.2013.355 · Cited by 688 · see citing works

<i>MTAP</i> deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells

Kryukov, G. V., Wilson, F. H., Ruth, J. R., Paulk, J., Tsherniak, A., Marlow, S. E., Vazquez, F., Weir, B. A., Fitzgerald, M. E., Tanaka, M., et al. (2016) · Science · doi:10.1126/science.aad5214 · Cited by 688 · see citing works

Histone Deacetylase Inhibitors in Clinical Studies as Templates for New Anticancer Agents

Mottamal, M., Zheng, S., Huang, T. L., & Wang, G. (2015) · Molecules · doi:10.3390/molecules20033898 · Cited by 687 · see citing works

Combination Epigenetic Therapy Has Efficacy in Patients with Refractory Advanced Non–Small Cell Lung Cancer

Juergens, R. A., Wrangle, J. M., Vendetti, F. P., Murphy, S. C., Zhao, M., Coleman, B., Sebree, R., Rodgers, K., Hooker, C. M., Franco, N. C., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0214 · Cited by 686 · see citing works

Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers

Bitler, B. G., Aird, K. M., Гарипов, А. Р., Li, H., Amatangelo, M. D., Kossenkov, A. V., Schultz, D., Liu, Q., Shih, I., Conejo-Garcia, J. R., et al. (2015) · Nature Medicine · doi:10.1038/nm.3799 · Cited by 683 · see citing works

Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells

Kim, K., Skora, A. D., Li, Z., Liu, Q., Tam, A. J., Blosser, R. L., Diaz, L. A., Papadopoulos, N., Kinzler, K. W., Vogelstein, B., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1410626111 · Cited by 676 · see citing works

Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia

Schenk, T., Chen, W. C., Göllner, S., Howell, L., Jin, L., Hebestreit, K., Klein, H.-U., Popescu, A. C., Burnett, A., Mills, K., et al. (2012) · Nature Medicine · doi:10.1038/nm.2661 · Cited by 672 · see citing works

Transcriptionally active chromatin recruits homologous recombination at DNA double-strand breaks

Aymard, F., Bugler, B., Schmidt, C. K., Guillou, E., Caron, P., Briois, S., Iacovoni, J. S., Daburon, V., Miller, K. M., Jackson, S. P., et al. (2014) · Nature Structural &amp; Molecular Biology · doi:10.1038/nsmb.2796 · Cited by 668 · see citing works

Histone H3 serine 10 phosphorylation by Aurora B causes HP1 dissociation from heterochromatin

Hirota, T., Lipp, J., Toh, B., & Peters, J. (2005) · Nature · doi:10.1038/nature04254 · Cited by 662 · see citing works

Epigenetic Antagonism between Polycomb and SWI/SNF Complexes during Oncogenic Transformation

Wilson, B. G., Wang, X., Shen, X., McKenna, E. S., Lemieux, M. E., Cho, Y., Koellhoffer, E. C., Pomeroy, S. L., Orkin, S. H., & Roberts, C. W. M. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.09.006 · Cited by 649 · see citing works

Targeting MYCN in Neuroblastoma by BET Bromodomain Inhibition

Puissant, A., Frumm, S. M., Alexe, G., Bassil, C. F., Qi, J., Chanthery, Y. H., Nekritz, E. A., Zeid, R., Gustafson, W. C., Greninger, P., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0418 · Cited by 637 · see citing works

Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer

Shu, S., Lin, C. Y., He, H. H., Witwicki, R. M., Tabassum, D. P., Roberts, J. M., Janiszewska, M., Jin Huh, S., Liang, Y., Ryan, J., et al. (2016) · Nature · doi:10.1038/nature16508 · Cited by 632 · see citing works

CREBBP mutations in relapsed acute lymphoblastic leukaemia

Mullighan, C. G., Zhang, J., Kasper, L. H., Lerach, S., Payne-Turner, D., Phillips, L. A., Heatley, S. L., Holmfeldt, L., Collins-Underwood, J. R., Ma, J., et al. (2011) · Nature · doi:10.1038/nature09727 · Cited by 628 · see citing works

PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors

Lee, W., Teckie, S., Wiesner, T., Ran, L., Granada, C. N. P., Lin, M., Zhu, S., Cao, Z., Liang, Y., Sboner, A., et al. (2014) · Nature Genetics · doi:10.1038/ng.3095 · Cited by 618 · see citing works

Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation

Yap, D., Chu, J., Berg, T., Schapira, M., Cheng, S., Moradian, A., Morin, R. D., Mungall, A. J. J., Meissner, B., Boyle, M., et al. (2010) · Blood · doi:10.1182/blood-2010-11-321208 · Cited by 609 · see citing works

Disordered methionine metabolism in MTAP/CDKN2A-deleted cancers leads to dependence on PRMT5

Mavrakis, K. J., McDonald, E. R., Schlabach, M. R., Billy, E., Hoffman, G. R., deWeck, A., Ruddy, D. A., Venkatesan, K., Yu, J., McAllister, G., et al. (2016) · Science · doi:10.1126/science.aad5944 · Cited by 607 · see citing works

The genetic landscape of mutations in Burkitt lymphoma

Love, C., Sun, Z., Jima, D. D., Li, G., Zhang, J., Miles, R. R., Richards, K. L., Dunphy, C. H., Choi, W. W. L., Srivastava, G., et al. (2012) · Nature Genetics · doi:10.1038/ng.2468 · Cited by 598 · see citing works

Fumarate is an epigenetic modifier that elicits epithelial-to-mesenchymal transition

Sciacovelli, M., Gonçalves, E., Johnson, T. I., Zecchini, V. R., da Costa, A. S. H., Gaude, E., Drubbel, A. V., Theobald, S. J., Abbo, S. R., Tran, M. G. B., et al. (2016) · Nature · doi:10.1038/nature19353 · Cited by 584 · see citing works

The Spectrum of SWI/SNF Mutations, Ubiquitous in Human Cancers

Shain, A. H., & Pollack, J. R. (2013) · PLoS ONE · doi:10.1371/journal.pone.0055119 · Cited by 578 · see citing works

The histone demethylase KDM1A sustains the oncogenic potential of MLL-AF9 leukemia stem cells

Harris, W. J., Huang, X., Lynch, J. T., Spencer, G. J., Hitchin, J. R., Li, Y., Ciceri, F., Blaser, J. G., Greystoke, B. F., Jordan, A. M., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.03.014 · Cited by 566 · see citing works

Hijacked in cancer: the MLL/KMT2 family of methyltransferases

Rao, R., & Dou, Y. (2015) · Nature Reviews. Cancer · doi:10.1038/nrc3929 · Cited by 558 · see citing works

Epigenetic Reactivation of Tumor Suppressor Genes by a Novel Small-Molecule Inhibitor of Human DNA Methyltransferases

Brueckner, B., Boy, R. G., Siedlecki, P. S., Musch, T., Kliem, H., Zielenkiewicz, P., Suhai, S., Wießler, M., & Lyko, F. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-2957 · Cited by 548 · see citing works

Non-coding recurrent mutations in chronic lymphocytic leukaemia

Puente, X. S., Beà, S., Valdés‐Mas, R., Villamor, N., Gutiérrez‐Abril, J., Martín-Subero, J. I., Munar, M., Rubio-Pérez, C., Jares, P., Aymerich, M., et al. (2016) · Nature · doi:10.1038/nature18910 · Cited by 546 · see citing works

BET inhibitor resistance emerges from leukaemia stem cells

Fong, C. Y., Gilan, O., Lam, E. Y. N., Rubin, A. F., Ftouni, S., Tyler, D., Stanley, K., Sinha, D., Yeh, P., Morison, J., et al. (2015) · Nature · doi:10.1038/nature14888 · Cited by 545 · see citing works

Aging and DNA methylation

Jung, M., & Pfeifer, G. P. (2015) · BMC Biology · doi:10.1186/s12915-015-0118-4 · Cited by 541 · see citing works

The PRMT5 arginine methyltransferase: many roles in development, cancer and beyond

Stopa, N., Krebs, J. E., & Shechter, D. (2015) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-015-1847-9 · Cited by 529 · see citing works

Selective Inhibition of EZH2 by EPZ-6438 Leads to Potent Antitumor Activity in EZH2 -Mutant Non-Hodgkin Lymphoma

Knutson, S. K., Kawano, S., Minoshima, Y., Warholic, N. M., Huang, K., Xiao, Y., Kadowaki, T., Uesugi, M., Kuznetsov, G., Kumar, N., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0773 · Cited by 529 · see citing works

Recurrent DNMT3A mutations in patients with myelodysplastic syndromes

Walter, M. J., Ding, L., Shen, D., Shao, J., Grillot, M., McLellan, M., Fulton, R., Schmidt, H., Kalicki-Veizer, J., O'Laughlin, M., et al. (2011) · Leukemia · doi:10.1038/leu.2011.44 · Cited by 527 · see citing works

ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors

Shen, J., Peng, Y., Wei, L., Zhang, W., Yang, L., Lan, L., Kapoor, P., Ju, Z., Mo, Q., Shih, I.-M., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0849 · Cited by 522 · see citing works

A DNA Hypomethylation Signature Predicts Antitumor Activity of LSD1 Inhibitors in SCLC

Mohammad, H. P., Smitheman, K. N., Kamat, C. D., Soong, D., Federowicz, K., Aller, G. S. V., Schneck, J., Carson, J. D., Liu, Y., Butticello, M., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.06.002 · Cited by 514 · see citing works

BRD4-NUT fusion oncogene: a novel mechanism in aggressive carcinoma.

French, C. A., Miyoshi, I., Kubonishi, I., Grier, H. E., Pérez‐Atayde, A. R., & Fletcher, J. A. (2003) · PubMed · Cited by 503 · see citing works

Transcriptional plasticity promotes primary and acquired resistance to BET inhibition

Rathert, P., Roth, M., Neumann, T., Muerdter, F., Roe, J., Muhar, M., Deswal, S., Cerny‐Reiterer, S., Peter, B., Jude, J., et al. (2015) · Nature · doi:10.1038/nature14898 · Cited by 503 · see citing works

Rearrangement of the MLL Gene in Acute Lymphoblastic and Acute Myeloid Leukemias with 11q23 Chromosomal Translocations

Thirman, M. J., Gill, H. J., Burnett, R. C., Mbangkollo, D., McCabe, N. R., Kobayashi, H., der Poel, S. Z.-V., Kaneko, Y., Morgan, R., Sandberg, A. A., et al. (1993) · New England Journal of Medicine · doi:10.1056/nejm199309233291302 · Cited by 501 · see citing works

Molecular mechanisms of leukemogenesis mediated by MLL fusion proteins

Ayton, P. M., & Cleary, M. L. (2001) · Oncogene · doi:10.1038/sj.onc.1204639 · Cited by 499 · see citing works

MTAP deletions in cancer create vulnerability to targeting of the MAT2A/PRMT5/RIOK1 axis

Marjon, K., Cameron, M. J., Quang, P., Clasquin, M. F., Mandley, E., Kunii, K., McVay, M., Choe, S., Kernytsky, A., Gross, S., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.03.043 · Cited by 485 · see citing works

Pharmacologic inhibition of histone demethylation as a therapy for pediatric brainstem glioma

Hashizume, R., Andor, N., Ihara, Y., Lerner, R., Gan, H., Chen, X., Fang, D., Huang, X., Tom, M. W., Ngo, V., et al. (2014) · Nature Medicine · doi:10.1038/nm.3716 · Cited by 476 · see citing works

TET2 and DNMT3A Mutations in Human T-Cell Lymphoma

Couronné, L., Bastard, C., & Bernard, O. (2012) · New England Journal of Medicine · doi:10.1056/nejmc1111708 · Cited by 472 · see citing works

Dosage-dependent modifiers of polycomb and antennapedia mutations in Drosophila.

Kennison, J. A., & Tamkun, J. W. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.21.8136 · Cited by 469 · see citing works

SETD2-Dependent Histone H3K36 Trimethylation Is Required for Homologous Recombination Repair and Genome Stability

Pfister, S. X., Ahrabi, S., Zalmas, L., Sarkar, S., Aymard, F., Bachrati, C. Z., Helleday, T., Legube, G., Thangue, N. B. L., Porter, A. C. G., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.05.026 · Cited by 465 · see citing works

HDAC Inhibition Upregulates PD-1 Ligands in Melanoma and Augments Immunotherapy with PD-1 Blockade

Woods, D. M., Sodré, A. L., Villagra, A., Sarnaik, A., Sotomayor, E. M., & Weber, J. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0077-t · Cited by 454 · see citing works

KDM4/JMJD2 Histone Demethylases: Epigenetic Regulators in Cancer Cells

Berry, W. L., & Janknecht, R. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4300 · Cited by 453 · see citing works

BRD–NUT oncoproteins: a family of closely related nuclear proteins that block epithelial differentiation and maintain the growth of carcinoma cells

French, C. A., Ramirez, C. L., Kolmakova, J., Hickman, T. T., Cameron, M. J., Thyne, M. E., Kutok, J. L., Toretsky, J. A., Tadavarthy, A. K., Kees, U. R., et al. (2007) · Oncogene · doi:10.1038/sj.onc.1210852 · Cited by 441 · see citing works

Expression of DNA methyltransferases DNMT1,3A, and 3B in normal hematopoiesis and in acute and chronic myelogenous leukemia

Mizuno, S., Chijiwa, T., Okamura, T., Akashi, K., Fukumaki, Y., Niho, Y., & Sasaki, H. (2001) · Blood · doi:10.1182/blood.v97.5.1172 · Cited by 439 · see citing works

The determinants of tumour immunogenicity

Blankenstein, T. J. F., Coulie, P. G., Gilboa, E., & Jaffee, E. M. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3246 · Cited by 437 · see citing works

TRIM24 links a non-canonical histone signature to breast cancer

Tsai, W.-W., Wang, Z., Yiu, T. T., Akdemir, K. C., Xia, W., Winter, S., Tsai, C., Shi, X., Schwarzer, D., Plunkett, W. K., et al. (2010) · Nature · doi:10.1038/nature09542 · Cited by 435 · see citing works

BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression

Zhu, H., Bengsch, F., Svoronos, N., Rutkowski, M. R., Bitler, B. G., Allegrezza, M. J., Yokoyama, Y., Kossenkov, A. V., Bradner, J. E., Conejo-Garcia, J. R., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.08.032 · Cited by 435 · see citing works

Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma

Li, M., Zhao, H., Zhang, X., Wood, L. D., Anders, R. A., Choti, M. A., Pawlik, T. M., Daniel, H. D. J., Kannangai, R., Offerhaus, G. J. A., et al. (2011) · Nature Genetics · doi:10.1038/ng.903 · Cited by 426 · see citing works

Functional epigenetics approach identifies BRM/SMARCA2 as a critical synthetic lethal target in BRG1-deficient cancers

Hoffman, G. R., Rahal, R., Buxton, F., Xiang, K., McAllister, G., Frias, E., Bagdasarian, L., Huber, J., Lindeman, A., Chen, D., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1316793111 · Cited by 421 · see citing works

Genetic Interactions in Cancer Progression and Treatment

Ashworth, A., Lord, C. J., & Reis-Filho, J. S. (2011) · Cell · doi:10.1016/j.cell.2011.03.020 · Cited by 421 · see citing works

Exome sequencing of serous endometrial tumors identifies recurrent somatic mutations in chromatin-remodeling and ubiquitin ligase complex genes

Gallo, M. L., O’Hara, A. J., Rudd, M. L., Urick, M. E., Hansen, N. F., O’Neil, N. J., Price, J. C., Zhang, S., England, B. M., Godwin, A. K., et al. (2012) · Nature Genetics · doi:10.1038/ng.2455 · Cited by 418 · see citing works

Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma

Sausen, M., Leary, R. J., Jones, S., Wu, J., Reynolds, C. P., Liu, X., Blackford, A. L., Parmigiani, G., Diaz, L. A., Papadopoulos, N., et al. (2012) · Nature Genetics · doi:10.1038/ng.2493 · Cited by 414 · see citing works

ARID1B is a specific vulnerability in ARID1A-mutant cancers

Helming, K., Wang, X., Wilson, B. G., Vázquez, F., Haswell, J. R., Manchester, H. E., Kim, Y., Kryukov, G. V., Ghandi, M., Aguirre, A. J., et al. (2014) · Nature Medicine · doi:10.1038/nm.3480 · Cited by 410 · see citing works

SWI/SNF-mutant cancers depend on catalytic and non-catalytic activity of EZH2

Kim, K. H., Kim, W., Howard, T. P., Vázquez, F., Tsherniak, A., Wu, J. N., Wang, W., Haswell, J. R., Walensky, L. D., Hahn, W. C., et al. (2015) · Nature Medicine · doi:10.1038/nm.3968 · Cited by 407 · see citing works

The murine SNF5/INI1 chromatin remodeling factor is essential for embryonic development and tumor suppression

Klochendler‐Yeivin, A., Fiette, L., Barra, J., Muchardt, C., Babinet, C., & Yaniv, M. (2000) · EMBO Reports · doi:10.1093/embo-reports/kvd129 · Cited by 405 · see citing works

Histone deacetylase 8 in neuroblastoma tumorigenesis

Oehme, I., Deubzer, H. E., Wegener, D., Pickert, D., Linke, J.-P., Hero, B., Kopp-Schneider, A., Westermann, F., Ulrich, S. M., von Deimling, A., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0684 · Cited by 398 · see citing works

SDH mutations in cancer

Bardella, C., Pollard, P. J., & Tomlinson, I. (2011) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2011.07.003 · Cited by 395 · see citing works

THE POLYCOMB AND TRITHORAX GROUP PROTEINS OF DROSOPHILA: Trans-Regulators of Homeotic Gene Function

Kennison, J. A. (1995) · Annual Review of Genetics · doi:10.1146/annurev.ge.29.120195.001445 · Cited by 395 · see citing works

Alterations of immune response of non-small cell lung cancer with Azacytidine

Wrangle, J. M., Wang, W., Koch, A., Easwaran, H., Mohammad, H. P., Pan, X., Vendetti, F. P., Criekinge, W. V., DeMeyer, T., Du, Z., et al. (2013) · Oncotarget · doi:10.18632/oncotarget.1542 · Cited by 385 · see citing works

ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A

Williamson, C. T., Miller, R., Pemberton, H. N., Jones, S. E., Campbell, J., Konde, A., Badham, N., Rafiq, R., Brough, R., Gulati, A., et al. (2016) · Nature Communications · doi:10.1038/ncomms13837 · Cited by 382 · see citing works

Loss of BRG1/BRM in human lung cancer cell lines and primary lung cancers: correlation with poor prognosis.

Reisman, D., Sciarrotta, J., Wang, W., Funkhouser, W. K., & Weissman, B. E. (2003) · PubMed · Cited by 381 · see citing works

FDA Approval: Belinostat for the Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma

Lee, H.-Z., Kwitkowski, V. E., Valle, P. L. D., Ricci, M., Saber, H., Habtemariam, B. A., Bullock, J. M., Bloomquist, E. W., Shen, Y. L., Chen, X.-H., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3119 · Cited by 365 · see citing works

Natural Killer Cell–Mediated Lysis of Hepatoma Cells via Specific Induction of NKG2D Ligands by the Histone Deacetylase Inhibitor Sodium Valproate

Armeanu, S., Bitzer, M., Lauer, U. M., Venturelli, S., Pathil, A., Krusch, M., Kaiser, S., Jobst, J., Smirnow, I., Wagner, A., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4252 · Cited by 359 · see citing works

Adverse Outcomes in Clear Cell Renal Cell Carcinoma with Mutations of 3p21 Epigenetic Regulators BAP1 and SETD2 : A Report by MSKCC and the KIRC TCGA Research Network

Hakimi, A. A., Ostrovnaya, I., Reva, B. A., Schultz, N. D., Chen, Y., Gönen, M., Liu, H., Takeda, S., Voss, M. H., Tickoo, S. K., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3886 · Cited by 358 · see citing works

An inhibitor of KDM5 demethylases reduces survival of drug-tolerant cancer cells

Vinogradova, M. V., Gehling, V. S., Gustafson, A. E., Arora, S., Tindell, C., WILSON, C. A., Williamson, K. E., Guler, G. D., Gangurde, P., Manieri, W., et al. (2016) · Nature Chemical Biology · doi:10.1038/nchembio.2085 · Cited by 358 · see citing works

Targeted Disruption of the EZH2/EED Complex Inhibits EZH2-dependent Cancer

Kim, W., Bird, G. H., Neff, T., Guo, G., Kerényi, M., Walensky, L., & Orkin, S. (2013) · Nature Chemical Biology · doi:10.1038/nchembio.1331 · Cited by 357 · see citing works

Conservation and Rewiring of Functional Modules Revealed by an Epistasis Map in Fission Yeast

Roguev, A., Bandyopadhyay, S., Zofall, M., Zhang, K., Fischer, T., Collins, S. R., Qu, H., Shales, M., Park, H.-O., Hayles, J., et al. (2008) · Science · doi:10.1126/science.1162609 · Cited by 352 · see citing works

Activation and transposition of endogenous retroviral elements in hypomethylation induced tumors in mice

Howard, G., Eiges, R., Gaudet, F., Jaenisch, R., & Eden, A. (2007) · Oncogene · doi:10.1038/sj.onc.1210631 · Cited by 341 · see citing works

Tip60 is a haplo-insufficient tumour suppressor required for an oncogene-induced DNA damage response

Gorrini, C., Squatrito, M., Luise, C., Syed, N., Perna, D., Wark, L., Martinato, F., Sardella, D., Verrecchia, A., Bennett, S., et al. (2007) · Nature · doi:10.1038/nature06055 · Cited by 341 · see citing works

HDAC Inhibitors Enhance T-Cell Chemokine Expression and Augment Response to PD-1 Immunotherapy in Lung Adenocarcinoma

Zheng, H., Zhao, W., Yan, C., Watson, C. C., Massengill, M. T., Xie, M., Massengill, C., Noyes, D. R., Martinez, G. V., Afzal, R., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2584 · Cited by 339 · see citing works

SMARCB1/INI1 Tumor Suppressor Gene Is Frequently Inactivated in Epithelioid Sarcomas

Modena, P., Lualdi, E., Facchinetti, F., Galli, L., Teixeira, M. R., Pilotti, S., & Sozzi, G. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3050 · Cited by 335 · see citing works

Highly penetrant, rapid tumorigenesis through conditional inversion of the tumor suppressor gene Snf5

Roberts, C. W. M., Leroux, M. M., Fleming, M. D., & Orkin, S. H. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00185-x · Cited by 333 · see citing works

Histone H3.3 Mutations Drive Pediatric Glioblastoma through Upregulation of MYCN

Bjerke, L. M., Mackay, A. G., Nandhabalan, M., Burford, A., Jury, A., Popov, S., Bax, D. A., Carvalho, D. M., Taylor, K. R., Vinci, M., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0426 · Cited by 319 · see citing works

DNA methyltransferase inhibitors and their emerging role in epigenetic therapy of cancer.

Gnyszka, A., Jastrzębski, Z., & Flis, S. (2013) · PubMed · Cited by 312 · see citing works

Targeting MLL1 H3K4 Methyltransferase Activity in Mixed-Lineage Leukemia

Cao, F., Townsend, E. C., Karataş, H., Xu, J., Li, L., Lee, S. H. F., Liu, L., Chen, Y., Ouillette, P. D., Zhu, J., et al. (2014) · Molecular Cell · doi:10.1016/j.molcel.2013.12.001 · Cited by 306 · see citing works

A Synthetic Lethality–Based Strategy to Treat Cancers Harboring a Genetic Deficiency in the Chromatin Remodeling Factor BRG1

Oike, T., Ogiwara, H., Tominaga, Y., Ito, K., Ando, O., Tsuta, K., Mizukami, T., Shimada, Y., Isomura, H., Komachi, M., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4593 · Cited by 305 · see citing works

Methylation of histone H3 lysine 36 enhances DNA repair by nonhomologous end-joining

Fnu, S., Williamson, E. A., Haro, L. P. D., Brenneman, M. A., Wray, J. W., Shaheen, M. F., Radhakrishnan, K., Lee, S., Nickoloff, J. A., & Hromas, R. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1013571108 · Cited by 300 · see citing works

Inhibiting WEE1 Selectively Kills Histone H3K36me3-Deficient Cancers by dNTP Starvation

Pfister, S. X., Markkanen, E., Jiang, Y., Sarkar, S., Woodcock, M., Orlando, G., Mavrommati, I., Pai, C., Zalmas, L., Drobnitzky, N., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.09.015 · Cited by 300 · see citing works

Cancer-associated IDH mutations: biomarker and therapeutic opportunities

Yen, K. E., Bittinger, M. A., Su, S. M., & Fantin, V. R. (2010) · Oncogene · doi:10.1038/onc.2010.444 · Cited by 296 · see citing works

Activation of MHC Class I, II, and CD40 Gene Expression by Histone Deacetylase Inhibitors

Magner, W. J., Kazim, A. L., Stewart, C., Romano, M. A., Catalano, G., Grande, C., Keiser, N., Santaniello, F., & Tomasi, T. B. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.12.7017 · Cited by 294 · see citing works

Mutations in SETD2 and genes affecting histone H3K36 methylation target hemispheric high-grade gliomas

Fontebasso, A. M., Schwartzentruber, J., Khuong-Quang, D.-A., Liu, X.-Y., Sturm, D., Korshunov, A., Jones, D., Witt, H., Kool, M., Albrecht, S., et al. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1095-8 · Cited by 291 · see citing works

Target gene context influences the transcriptional requirement for the KAT3 family of CBP and p300 histone acetyltransferases

Bedford, D. C., Kasper, L. H., Fukuyama, T., & Brindle, P. K. (2010) · Epigenetics · doi:10.4161/epi.5.1.10449 · Cited by 290 · see citing works

A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition

Ropero, S., Fraga, M. F., Ballestar, E., Hamelin, R., Yamamoto, H., Boix-Chornet, M., Caballero, R., Alaminos, M., Setién, F., Paz, M. F., et al. (2006) · Nature Genetics · doi:10.1038/ng1773 · Cited by 290 · see citing works

Discovery of an in Vivo Chemical Probe of the Lysine Methyltransferases G9a and GLP

Liu, F., Baršytė-Lovejoy, D., Li, F., Xiong, Y., Korboukh, V. K., Huang, X., Allali‐Hassani, A., Janzen, W. P., Roth, B. L., Frye, S. V., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm401480r · Cited by 285 · see citing works

The histone H3.3K36M mutation reprograms the epigenome of chondroblastomas

Fang, D., Gan, H., Lee, J., Han, J., Wang, Z., Riester, S. M., Jin, L. G., Chen, J., Zhou, H., Wang, J., et al. (2016) · Science · doi:10.1126/science.aae0065 · Cited by 285 · see citing works

Catalytic site remodelling of the DOT1L methyltransferase by selective inhibitors

Yu, W., Chory, E. J., Wernimont, A. K., Tempel, W., Scopton, A. P., Alexander Joel Federation, Marineau, J., Qi, J., Baršytė-Lovejoy, D., Yi, J., et al. (2012) · Nature Communications · doi:10.1038/ncomms2304 · Cited by 283 · see citing works

The SMARCA2/4 ATPase Domain Surpasses the Bromodomain as a Drug Target in SWI/SNF-Mutant Cancers: Insights from cDNA Rescue and PFI-3 Inhibitor Studies

Vangamudi, B., Paul, T. A., Shah, P. K., Kost-Alimova, M., Nottebaum, L., Shi, X., Zhan, Y., Leo, E., Mahadeshwar, H. S., Protopopov, A., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3798 · Cited by 281 · see citing works

Vulnerabilities of mutant SWI/SNF complexes in cancer

Helming, K., Wang, X.-F., & Roberts, C. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.07.018 · Cited by 278 · see citing works

Over-Expression of LSD1 Promotes Proliferation, Migration and Invasion in Non-Small Cell Lung Cancer

Lv, T., Yuan, D., Miao, X., Lv, Y., Zhan, P., Shen, X., & Song, Y. (2012) · PLoS ONE · doi:10.1371/journal.pone.0035065 · Cited by 275 · see citing works

Regulation of distinct biological activities of the NF-?B transcription factor complex by acetylation

Chen, L., & Greene, W. C. (2003) · Journal of Molecular Medicine · doi:10.1007/s00109-003-0469-0 · Cited by 275 · see citing works

PRC2 Epigenetically Silences Th1-Type Chemokines to Suppress Effector T-Cell Trafficking in Colon Cancer

Nagarsheth, N., Peng, D., Kryczek, I., Wu, K., Li, W., Zhao, E., Zhao, L., Wei, S., Frankel, T. L., Vatan, L., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-1938 · Cited by 270 · see citing works

Dual Chromatin and Cytoskeletal Remodeling by SETD2

Park, I. Y., Powell, R. T., Tripathi, D. N., Dere, R., Ho, T. H., Blasius, T. L., Chiang, Y.-C., Davis, I. J., Fahey, C. C., Hacker, K. E., et al. (2016) · Cell · doi:10.1016/j.cell.2016.07.005 · Cited by 268 · see citing works

TRIM24 Is an Oncogenic Transcriptional Activator in Prostate Cancer

Groner, A. C., Cato, L., de Tribolet-Hardy, J., Bernasocchi, T., Janoušková, H., Melchers, D., Houtman, R., Cato, A. C. B., Tschopp, P., Gu, L., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.04.012 · Cited by 267 · see citing works

SETD2 is required for DNA double-strand break repair and activation of the p53-mediated checkpoint

Carvalho, S., Vítor, A. C., Sridhara, S. R. C., Martins, F. B., Raposo, A. C., Desterro, J. M. P., Ferreira, J. A., & de Almeida, S. F. (2014) · eLife · doi:10.7554/elife.02482 · Cited by 266 · see citing works

SWI/SNF Mediates Polycomb Eviction and Epigenetic Reprogramming of the INK4b-ARF-INK4a Locus

Kia, S. K., Gorski, M. M., Giannakopoulos, S., & Verrijzer, C. P. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.02019-07 · Cited by 265 · see citing works

Histone demethylase JMJD2B coordinates H3K4/H3K9 methylation and promotes hormonally responsive breast carcinogenesis

Shi, L., Sun, L., Li, Q., Liang, J., Yu, W., Yi, X., Yang, X., Li, Y., Han, X., Zhang, Y., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1017374108 · Cited by 261 · see citing works

Harnessing synthetic lethal interactions in anticancer drug discovery

Chan, D. A., & Giaccia, A. J. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3374 · Cited by 260 · see citing works

Loss-of-function mutations in SMARCE1 cause an inherited disorder of multiple spinal meningiomas

Smith, M. J., O’Sullivan, J., Bhaskar, S. S., Hadfield, K. D., Poke, G., Caird, J., Sharif, S., Eccles, D., FitzPatrick, D. R., Rawluk, D. J. R., et al. (2013) · Nature Genetics · doi:10.1038/ng.2552 · Cited by 260 · see citing works

Cancer Cells Become Susceptible to Natural Killer Cell Killing after Exposure to Histone Deacetylase Inhibitors Due to Glycogen Synthase Kinase-3–Dependent Expression of MHC Class I–Related Chain A and B

Skov, S., Pedersen, M. T., Andresen, L. O., Straten, P. T., Woetmann, A., & Ødum, N. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0599 · Cited by 260 · see citing works

TET proteins and the control of cytosine demethylation in cancer

Scourzic, L., Mouly, E., & Bernard, O. (2015) · Genome Medicine · doi:10.1186/s13073-015-0134-6 · Cited by 251 · see citing works

MLL-AF9-Induced Leukemogenesis Requires Co-Expression of the Wild Type Mll Allele

Thiel, A. T., Blessington, P., Zou, T., Feather, D., Wu, X.-J., Yan, J.-Z., Zhang, H., Liu, Z.-G., Ernst, P., Koretzky, G., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.034 · Cited by 249 · see citing works

PBAF chromatin-remodeling complex requires a novel specificity subunit, BAF200, to regulate expression of selective interferon-responsive genesPreprint

Yan, Z., Cui, K., Murray, D., Chen, L., Xue, Y., Gerstein, A. V., Parsons, R. E., Zhao, K., & Wang, W. (2005) · Genes & Development · doi:10.1101/gad.1323805 · Cited by 247 · see citing works

Current state of melanoma diagnosis and treatment

Davis, L. E., Shalin, S. C., & Tackett, A. J. (2019) · Cancer Biology & Therapy · doi:10.1080/15384047.2019.1640032 · Cited by 945 · see citing works

Heterochromatin: Guardian of the Genome

Janssen, A., Colmenares, S. U., & Karpen, G. H. (2018) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-100617-062653 · Cited by 500 · see citing works

In vivo target gene activation via CRISPR/Cas9-mediated trans-epigenetic modulation

Liao, H.-K., Hatanaka, F., Araoka, T., Reddy, P., Wu, M.-Z., Sui, Y., Yamauchi, T., Sakurai, M., O’Keefe, D. D., Núñez-Delicado, E., et al. (2017) · Cell · doi:10.1016/j.cell.2017.10.025 · Cited by 451 · see citing works

Bromodomains: a new target class for drug development

Cochran, A. G., Conery, A. R., & Sims, R. J. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0030-7 · Cited by 438 · see citing works

The emerging role of epigenetic therapeutics in immuno-oncology

Topper, M. J., Vaz, M., Marrone, K. A., Brahmer, J. R., & Baylin, S. B. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0266-5 · Cited by 433 · see citing works

Synthetic lethal therapies for cancer: what’s next after PARP inhibitors?

Ashworth, A., & Lord, C. J. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0055-6 · Cited by 420 · see citing works

Targeting epigenetic modifications in cancer therapy: erasing the roadmap to cancer

Mohammad, H. P., Barbash, O., & Creasy, C. L. (2019) · Nature Medicine · doi:10.1038/s41591-019-0376-8 · Cited by 418 · see citing works

Altered cellular metabolism in gliomas — an emerging landscape of actionable co-dependency targets

Bi, J., Chowdhry, S., Wu, S., Zhang, W., Masui, K., & Mischel, P. S. (2019) · Nature reviews. Cancer · doi:10.1038/s41568-019-0226-5 · Cited by 348 · see citing works

WD40 repeat domain proteins: a novel target class?

Schapira, M., Tyers, M., Torrent, M., & Arrowsmith, C. H. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.179 · Cited by 335 · see citing works

Epigenetic modulation of antitumor immunity for improved cancer immunotherapy

Dai, E., Zhu, Z., Wahed, S., Qu, Z., Storkus, W. J., & Guo, Z. S. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01464-x · Cited by 332 · see citing works

Epigenetics and Trained Immunity

van der Heijden, C. D. C. C., Noz, M. P., Joosten, L. A. B., Netea, M. G., Riksen, N. P., & Keating, S. T. (2017) · Antioxidants and Redox Signaling · doi:10.1089/ars.2017.7310 · Cited by 284 · see citing works

Histone methylation and the DNA damage response

Gong, F., & Miller, K. M. (2017) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2017.09.003 · Cited by 247 · see citing works

Peptide-Drug Conjugates and Their Targets in Advanced Cancer Therapies

Hoppenz, P., Els‐Heindl, S., & Beck‐Sickinger, A. G. (2020) · Frontiers in Chemistry · doi:10.3389/fchem.2020.00571 · Cited by 248 · see citing works

EZH2-Targeted Therapies in Cancer: Hype or a Reality

Eich, M., Athar, M., Ferguson, J. E., & Varambally, S. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-2147 · Cited by 246 · see citing works

Epigenetics and beyond: targeting writers of protein lysine methylation to treat disease

Bhat, K. P., Kanıskan, H. Ü., Jin, J. J., & Gozani, O. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-00108-x · Cited by 243 · see citing works

Cancer Metabolism: Current Understanding and Therapies

Counihan, J. L., Grossman, E. A., & Nomura, D. K. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00775 · Cited by 229 · see citing works

Targeting EZH2 in cancer therapy

Yamagishi, M., & Uchimaru, K. (2017) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000390 · Cited by 224 · see citing works

The epigenomics of sarcoma

Nacev, B. A., Jones, K. B., Intlekofer, A. M., Yu, J., Allis, C. D., Tap, W. D., Ladanyi, M., & Nielsen, T. O. (2020) · Nature reviews. Cancer · doi:10.1038/s41568-020-0288-4 · Cited by 211 · see citing works

Targeting epigenetic and posttranslational modifications regulating ferroptosis for the treatment of diseases

Wang, Y., Hu, J., Wu, S., Fleishman, J. S., Li, Y., Xu, Y.-S., Zou, W., Wang, J., Feng, Y., Chen, J., et al. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01720-0 · Cited by 220 · see citing works

Stem Cell Plasticity and Dormancy in the Development of Cancer Therapy Resistance

Angelis, M. L. D., Francescangeli, F., Torre, F. L., & Zeuner, A. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00626 · Cited by 203 · see citing works

Crosstalk between metabolic reprogramming and epigenetics in cancer: updates on mechanisms and therapeutic opportunities

Ge, T., Gu, X., Jia, R., Ge, S., Chai, P., Zhuang, A., & Fan, X. (2022) · 癌症：英文版 · doi:10.1002/cac2.12374 · Cited by 206 · see citing works

Targeting Excessive EZH1 and EZH2 Activities for Abnormal Histone Methylation and Transcription Network in Malignant Lymphomas

Yamagishi, M., Hori, M., Fujikawa, D., Ohsugi, T., Honma, D., Adachi, N., Katano, H., Hishima, T., Kobayashi, S., Nakano, K., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.10.083 · Cited by 192 · see citing works

Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer

Cabanos, H. F., & Hata, A. N. (2021) · Cancers · doi:10.3390/cancers13112666 · Cited by 189 · see citing works

The impact of tumour pH on cancer progression: strategies for clinical intervention

Ward, C., Meehan, J., Gray, M., Murray, A. F., Argyle, D. J., Kunkler, I. H., & Langdon, S. P. (2020) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2020.00005 · Cited by 180 · see citing works

Dysregulated haematopoietic stem cell behaviour in myeloid leukaemogenesis

Yamashita, M., Dellorusso, P. V., Olson, O. C., & Passegue, E. A. (2020) · Nature reviews. Cancer · doi:10.1038/s41568-020-0260-3 · Cited by 182 · see citing works

Advances in synthetic lethality for cancer therapy: cellular mechanism and clinical translation

Topatana, W., Juengpanich, S., Li, S., Cao, J., Hu, J., Lee, J., Suliyanto, K., Ma, D., Zhang, B., Chen, M., et al. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00956-5 · Cited by 182 · see citing works

Advances in multidisciplinary therapy for meningiomas

Brastianos, P. K., Galanis, E., Butowski, N. A., Chan, J. W. S., Dunn, I. F., Goldbrunner, R., Herold‐Mende, C. C., Ippen, F. M., Mawrin, C., McDermott, M. W., et al. (2018) · Neuro-Oncology · doi:10.1093/neuonc/noy136 · Cited by 165 · see citing works

Targeting the replication stress response in cancer

Forment, J. V., & O’Connor, M. J. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.03.005 · Cited by 159 · see citing works

Harnessing big ‘omics’ data and AI for drug discovery in hepatocellular carcinoma

Chen, B., Garmire, L., Calvisi, D. F., Chua, M.-S., Kelley, R. K., & Chen, X. (2020) · Nature Reviews Gastroenterology &amp; Hepatology · doi:10.1038/s41575-019-0240-9 · Cited by 154 · see citing works

On the design principles of peptide–drug conjugates for targeted drug delivery to the malignant tumor site

Vrettos, E. I., Mező, G., & Tzakos, A. G. (2018) · Beilstein Journal of Organic Chemistry · doi:10.3762/bjoc.14.80 · Cited by 152 · see citing works

Drug-Tolerant Persister Cells in Cancer Therapy Resistance

Dhanyamraju, P. K., Schell, T. D., Amin, S., & Robertson, G. P. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-3844 · Cited by 145 · see citing works

mTOR Cross-Talk in Cancer and Potential for Combination Therapy

Conciatori, F., Ciuffreda, L., Bazzichetto, C., Falcone, I., Pilotto, S., Bria, E., Cognetti, F., & Milella, M. (2018) · Cancers · doi:10.3390/cancers10010023 · Cited by 144 · see citing works

Dancing with the DNA damage response: next-generation anti-cancer therapeutic strategies

Minchom, A. R., Aversa, C., & Lopez, J. S. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835918786658 · Cited by 137 · see citing works

Drug tolerant persister cell plasticity in cancer: a revolutionary strategy for more effective anticancer therapies

He, J., Qiu, Z., Fan, J., Xie, X., Sheng, Q., & Sui, X. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01891-4 · Cited by 133 · see citing works

Epigenetics in hepatocellular carcinoma development and therapy: The tip of the iceberg

Fernández-Barrena, M. G., Arechederra, M., Colyn, L., Berasain, C., & Avila, M. A. (2020) · JHEP Reports · doi:10.1016/j.jhepr.2020.100167 · Cited by 126 · see citing works

A chemical toolbox for the study of bromodomains and epigenetic signaling

Wu, Q., Heidenreich, D. J., Zhou, S., Ackloo, S. Z., Krämer, A., Nakka, K. K., Lima‐Fernandes, E., Deblois, G., Duan, S., Vellanki, R. N., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09672-2 · Cited by 120 · see citing works

Mutational landscape of cancer-driver genes across human cancers

Sinkala, M. (2023) · Scientific Reports · doi:10.1038/s41598-023-39608-2 · Cited by 130 · see citing works

Emerging epigenetic-modulating therapies in lymphoma

Sermer, D. J., Pasqualucci, L., Wendel, H., Melnick, A. M., & Younes, A. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0190-8 · Cited by 120 · see citing works

LSD1/KDM1A, a Gate-Keeper of Cancer Stemness and a Promising Therapeutic Target

Karakaidos, P., Verigos, J., & Magklara, A. (2019) · Cancers · doi:10.3390/cancers11121821 · Cited by 108 · see citing works

Medulloblastoma: Molecular Classification-Based Personal Therapeutics

Archer, T. C., Mahoney, E. L., & Pomeroy, S. L. (2017) · Neurotherapeutics · doi:10.1007/s13311-017-0526-y · Cited by 101 · see citing works

Targeting epigenetic regulatory machinery to overcome cancer therapy resistance

Guo, L., Lee, Y., Zhou, Y., & Huang, Y. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.12.022 · Cited by 96 · see citing works

Preserving genome integrity and function: the DNA damage response and histone modifications

Kim, J. J., Lee, S. Y., & Miller, K. M. (2019) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.1080/10409238.2019.1620676 · Cited by 95 · see citing works

Resistance to Epigenetic-Targeted Therapy Engenders Tumor Cell Vulnerabilities Associated with Enhancer Remodeling

Iniguez, A. B., Alexe, G., Wang, E. J., Roti, G., Patel, S., Chen, L., Kitara, S., Conway, A. S., Robichaud, A. L., Stolte, B., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.11.005 · Cited by 90 · see citing works

Olaparib hydroxamic acid derivatives as dual PARP and HDAC inhibitors for cancer therapy

Yuan, Z., Chen, S., Sun, Q., Wang, N., Li, D., Miao, S., Gao, C., Chen, Y., Tan, C., & Jiang, Y. (2017) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2017.05.058 · Cited by 90 · see citing works

Enzymatic Transition States and Drug Design

Schramm, V. L. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00369 · Cited by 89 · see citing works

Epigenetic reprogramming using 5-azacytidine promotes an anti-cancer response in pancreatic adenocarcinoma cells

Gailhouste, L., Liew, L. C., Hatada, I., Nakagama, H., & Ochiya, T. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0487-z · Cited by 90 · see citing works

Centromere and Pericentromere Transcription: Roles and Regulation … in Sickness and in Health

Smurova, K., & Wulf, P. D. (2018) · Frontiers in Genetics · doi:10.3389/fgene.2018.00674 · Cited by 84 · see citing works

Lysine methylation of transcription factors in cancer

Han, D. H., Huang, M., Wang, T., Li, Z., Chen, Y., Liu, C., Lei, Z., & Chu, X. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1524-2 · Cited by 89 · see citing works

Endometriosis-associated ovarian carcinomas: insights into pathogenesis, diagnostics, and therapeutic targets—a narrative review

Samartzis, E. P., Labidi‐Galy, S. I., Moschetta, M., Uccello, M., Kalaitzopoulos, D. R., Fidalgo, J. A. P., & Boussios, S. (2020) · Annals of Translational Medicine · doi:10.21037/atm-20-3022a · Cited by 82 · see citing works

Targeting EHMT2 reverses EGFR-TKI resistance in NSCLC by epigenetically regulating the PTEN/AKT signaling pathway

Wang, L., Dong, X., Ren, Y., Luo, J., Liu, P., Su, D., & Yang, X. (2018) · Cell Death and Disease · doi:10.1038/s41419-017-0120-6 · Cited by 79 · see citing works

Allele-Specific DNA Methylation and Its Interplay with Repressive Histone Marks at Promoter-Mutant TERT Genes

Stern, J. L., Paucek, R. D., Huang, F. W., Ghandi, M., Nwumeh, R., Costello, J. C., & Cech, T. R. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.12.001 · Cited by 77 · see citing works

Differentiation Therapy by Epigenetic Reconditioning Exerts Antitumor Effects on Liver Cancer Cells

Gailhouste, L., Liew, L. C., Yasukawa, K., Hatada, I., Tanaka, Y., Nakagama, H., & Ochiya, T. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.04.018 · Cited by 77 · see citing works

DOT1L Is a Novel Cancer Stem Cell Target for Triple-Negative Breast Cancer

Kurani, H., Razavipour, S. F., Harikumar, K. B., Dunworth, M., Ewald, A. J., Nasir, A., Pearson, G. W., Booven, D. V., Zhou, Z., Azzam, D. J., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1299 · Cited by 73 · see citing works

Targeting of peptide‐binding receptors on cancer cells with peptide‐drug conjugates

Worm, D. J., Els‐Heindl, S., & Beck‐Sickinger, A. G. (2020) · Peptide Science · doi:10.1002/pep2.24171 · Cited by 73 · see citing works

Dual inhibitors of DNMT and HDAC induce viral mimicry to induce antitumour immunity in breast cancer

Huang, W., Zhu, Q., Shi, Z., Tu, Y., Li, Q., Zheng, W., Yuan, Z., Li, L., Zu, X., Hao, Y., et al. (2024) · Cell Death Discovery · doi:10.1038/s41420-024-01895-7 · Cited by 71 · see citing works

Genomic characterization of genes encoding histone acetylation modulator proteins identifies therapeutic targets for cancer treatment

Hu, Z., Zhou, J., Jiang, J., Yuan, J., Zhang, Y., Wei, X., Loo, N., Wang, Y., Pan, Y., Zhang, T., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-08554-x · Cited by 70 · see citing works

USP7 deubiquitinates and stabilizes EZH2 in prostate cancer cells

Lee, J. E., Park, C. M., & Kim, J. H. (2020) · Genetics and Molecular Biology · doi:10.1590/1678-4685-gmb-2019-0338 · Cited by 70 · see citing works

Discovery of SMD-3040 as a Potent and Selective SMARCA2 PROTAC Degrader with Strong in vivo Antitumor Activity

Yang, L., Tu, W., Huang, L., Miao, B., Kaneshige, A., Jiang, W., Leng, L., Wang, M., Wen, B., Sun, D., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00953 · Cited by 69 · see citing works

A Multi-Omics Perspective of Quantitative Trait Loci in Precision Medicine

Ye, Y., Zhang, Z., Liu, Y., Diao, L., & Han, L. (2020) · Trends in Genetics · doi:10.1016/j.tig.2020.01.009 · Cited by 64 · see citing works

An integrated genomic analysis of anaplastic meningioma identifies prognostic molecular signatures

Collord, G., Tarpey, P. S., Kurbatova, N., Martincorena, I., Morán, S., de Moura, M. C., Nagy, T., Bignell, G. R., Maura, F., Young, M. D., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-31659-0 · Cited by 62 · see citing works

Histone Deacetylases and Histone Deacetylase Inhibitors in Neuroblastoma

Phimmachanh, M., Han, J. Z. R., O’Donnell, Y. E. I., Latham, S. L., & Croucher, D. R. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.578770 · Cited by 61 · see citing works

Epigenetic Crosstalk between the Tumor Microenvironment and Ovarian Cancer Cells: A Therapeutic Road Less Traveled

Klymenko, Y., & Nephew, K. P. (2018) · Cancers · doi:10.3390/cancers10090295 · Cited by 61 · see citing works

Development of a versatile DNMT and HDAC inhibitor C02S modulating multiple cancer hallmarks for breast cancer therapy

Yuan, Z., Chen, S., Gao, C., Dai, Q., Zhang, C., Sun, Q., Lin, J., Guo, C., Chen, Y., & Jiang, Y. (2019) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2019.03.027 · Cited by 59 · see citing works

Relevance of HBx for Hepatitis B Virus-Associated Pathogenesis

Schollmeier, A., Glitscher, M., & Hildt, E. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054964 · Cited by 58 · see citing works

Connections between metabolism and epigenetics: mechanisms and novel anti-cancer strategy

Chen, C., Wang, Z., & Qin, Y. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.935536 · Cited by 60 · see citing works

Towards a more precise therapy in cancer: Exploring epigenetic complexity

Cossío, F. P., Esteller, M., & Berdasco, M. (2020) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2020.04.008 · Cited by 55 · see citing works

A Bimetallic Metal–Organic‐Framework‐Based Biomimetic Nanoplatform Enhances Anti‐Leukemia Immunity via Synchronizing DNA Demethylation and RNA Hypermethylation

Song, Y., Zhang, L., Wang, Y., Han, M., Wang, Z., Wang, N., Shao, B., Li, R., Cao, K., Song, M., et al. (2023) · Advanced Materials · doi:10.1002/adma.202210895 · Cited by 54 · see citing works

Differential DNA methylation in high-grade serous ovarian cancer (HGSOC) is associated with tumor behavior

Reyes, H. D., Devor, E. J., Warrier, A., Newtson, A. M., Mattson, J. N., Wagner, V. M., Duncan, G. N., Leslie, K. K., & Bosquet, J. G. (2019) · Scientific Reports · doi:10.1038/s41598-019-54401-w · Cited by 52 · see citing works

Phase I study of domatinostat (4 SC ‐202), a class I histone deacetylase inhibitor in patients with advanced hematological malignancies

von Tresckow, B., Sayehli, C. M., Aulitzky, W. E., Goebeler, M.-E., Schwab, M. G., Braz, E., Krauss, B., Krauss, R., Hermann, F., Bartz, R., et al. (2018) · European Journal Of Haematology · doi:10.1111/ejh.13188 · Cited by 52 · see citing works

Epigenetic therapy of Prader–Willi syndrome

Kim, Y., Wang, S. E., & Jiang, Y. (2019) · Translational research · doi:10.1016/j.trsl.2019.02.012 · Cited by 53 · see citing works

Mechanisms of low MHC I expression and strategies for targeting MHC I with small molecules in cancer immunotherapy

Kong, S., Zhang, J., Wang, L., Li, W., Guo, H., Weng, Q., He, Q., Lou, H., Ding, L., & Yang, B. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.217432 · Cited by 50 · see citing works

Drug Discovery and Chemical Biology of Cancer Epigenetics

Ribich, S. A., Harvey, D. M., & Copeland, R. A. (2017) · Cell chemical biology · doi:10.1016/j.chembiol.2017.08.020 · Cited by 49 · see citing works

Targeting EHMT2/ G9a for cancer therapy: Progress and perspective

Jan, S., Dar, M. I., Wani, R., Sandey, J., Mushtaq, I., Lateef, S., & Syed, S. H. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173827 · Cited by 48 · see citing works

Epigenetic drug discovery: a success story for cofactor interference

Ganesan, A. (2018) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2017.0069 · Cited by 48 · see citing works

Emerging roles of telomeric chromatin alterations in cancer

Cacchione, S., Biroccio, A., & Rizzo, A. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1030-5 · Cited by 46 · see citing works

An emerging role for cellular crosstalk in the cancer stem cell niche

Oshimori, N., Guo, Y., & Taniguchi, S. (2021) · The Journal of Pathology · doi:10.1002/path.5655 · Cited by 47 · see citing works

Recent progress in developing selective inhibitors of protein methyltransferases

Kanıskan, H. Ü., & Jin, J. J. (2017) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2017.06.013 · Cited by 44 · see citing works

Orally Bioavailable Proteolysis-Targeting Chimeras: An Innovative Approach in the Golden Era of Discovering Small-Molecule Cancer Drugs

Rej, R. K., Allu, S. R., Roy, J., Acharyya, R. K., Kiran, I. N. C., Addepalli, Y., & Dhamodharan, V. (2024) · Pharmaceuticals · doi:10.3390/ph17040494 · Cited by 42 · see citing works

Peptide–Drug Conjugates as Next-Generation Therapeutics: Exploring the Potential and Clinical Progress

Jadhav, K., Abhang, A., Kole, E. B., Gadade, D. D., Dusane, A., Iyer, A., Sharma, A., Rout, S. K., Gholap, A. D., Naik, J., et al. (2025) · Bioengineering · doi:10.3390/bioengineering12050481 · Cited by 42 · see citing works

UHRF1 inhibition epigenetically reprograms cancer stem cells to suppress the tumorigenic phenotype of hepatocellular carcinoma

Wang, Y., Hu, P., Wang, F., Xi, S., Wu, S., Sun, L.-Z., Du, Y., Zheng, J., Yang, H., Tang, M., et al. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-05895-w · Cited by 40 · see citing works

Targeting histone deacetylase suppresses tumor growth through eliciting METTL14‐modified m 6 A RNA methylation in ocular melanoma

Zhuang, A., Gu, X., Ge, T., Wang, S., Ge, S., Chai, P., Jia, R., & Fan, X. (2023) · 癌症：英文版 · doi:10.1002/cac2.12471 · Cited by 39 · see citing works

A multi-omic dissection of super-enhancer driven oncogenic gene expression programs in ovarian cancer

Kelly, M. R., Wiśniewska, K., Regner, M. J., Lewis, M. W., Perreault, A. A., Davis, E. S., Phanstiel, D. H., Parker, J. S., & Franco, H. L. (2022) · Nature Communications · doi:10.1038/s41467-022-31919-8 · Cited by 40 · see citing works

Oncogenic Viruses and the Epigenome: How Viruses Hijack Epigenetic Mechanisms to Drive Cancer

MacLennan, S., & Marra, M. A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119543 · Cited by 39 · see citing works

BET bromodomain inhibitor JQ1 preferentially suppresses EBV-positive nasopharyngeal carcinoma cells partially through repressing c-Myc

Li, N., Yang, L., Qi, X.-K., Lin, Y.-X., Xie, X., He, G.-P., Feng, Q.-S., Liu, L.-R., Xie, X., Zeng, Y., et al. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0789-1 · Cited by 39 · see citing works

The Unexpected Noncatalytic Roles of Histone Modifiers in Development and Disease

Aubert, Y., Egolf, S., & Capell, B. C. (2019) · Trends in Genetics · doi:10.1016/j.tig.2019.06.004 · Cited by 36 · see citing works

Epigenetic based synthetic lethal strategies in human cancers

Gao, A., & Guo, M. (2020) · Biomarker Research · doi:10.1186/s40364-020-00224-1 · Cited by 40 · see citing works

mTORC1 beyond anabolic metabolism: Regulation of cell death

Zhu, J., Wang, H., & Jiang, X. (2022) · The Journal of Cell Biology · doi:10.1083/jcb.202208103 · Cited by 41 · see citing works

Natural Bioactive Compounds Targeting Histone Deacetylases in Human Cancers: Recent Updates

Bouyahya, A., Hachlafi, N. E., Aanniz, T., Bourais, I., Mechchate, H., Benali, T., Shariati, M. A., Burkov, P., Lorenzo, J. M., Wilairatana, P., et al. (2022) · Molecules · doi:10.3390/molecules27082568 · Cited by 38 · see citing works

The Intricate Interplay between Epigenetic Events, Alternative Splicing and Noncoding RNA Deregulation in Colorectal Cancer

Amirkhah, R., Naderi‐Meshkin, H., Shah, J. S., Dunne, P. D., & Schmitz, U. (2019) · Cells · doi:10.3390/cells8080929 · Cited by 39 · see citing works

PROTAC: targeted drug strategy. Principles and limitations

Koroleva, O. A., Dutikova, Y. V., Trubnikov, A. V., Zenov, F. A., Manasova, E. V., Shtil, A. A., & Kurkin, A. V. (2022) · Russian Chemical Bulletin · doi:10.1007/s11172-022-3659-z · Cited by 38 · see citing works

Discrete and continuum phenotype-structured models for the evolution of cancer cell populations under chemotherapy

Stace, R. E. A., Stiehl, T., Chaplain, M. A. J., Marciniak-Czochra, A. K., & Lorenzi, T. (2020) · Mathematical Modelling of Natural Phenomena · doi:10.1051/mmnp/2019027 · Cited by 36 · see citing works

Design and Synthesis of Novel Epigenetic Inhibitors Targeting Histone Deacetylases, DNA Methyltransferase 1, and Lysine Methyltransferase G9a with In Vivo Efficacy in Multiple Myeloma

Rabal, O., José‐Eneriz, E. S., Agirre, X., Sánchez-Arias, J. A., de Miguel, I., Ordóñez, R., Gárate, L., Miranda, E., Sáez, E., Vilas‐Zornoza, A., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c02255 · Cited by 36 · see citing works

The oncogenic lysophosphatidylinositol (LPI)/GPR55 signaling

Calvillo-Robledo, A., Cervantes‐Villagrana, R. D., Morales, P., & Marichal‐Cancino, B. A. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.120596 · Cited by 36 · see citing works

CR2Cancer: a database for chromatin regulators in human cancer

Ru, B., Sun, J., Tong, Y., Wong, C. N., Chandra, A., Tang, A. T. S., Chow, L. K.-Y., Wun, W. L., Levitskaya, Z., & Zhang, J. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx877 · Cited by 35 · see citing works

Methylation of NRN1 is a novel synthetic lethal marker of PI3K‐Akt‐mTOR and ATR inhibitors in esophageal cancer

Du, W., Gao, A., Herman, J. G., Wang, L., Zhang, L., Jiao, S., & Guo, M. (2021) · Cancer Science · doi:10.1111/cas.14917 · Cited by 35 · see citing works

Selectively targeting individual bromodomain: Drug discovery and molecular mechanisms

Wang, Q., Shao, X., Leung, E. L., Chen, Y., & Yao, X. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105804 · Cited by 35 · see citing works

Multi-level advances in databases related to systems pharmacology in traditional Chinese medicine: a 60-year review

Fan, M., Jin, C., Li, D., Deng, Y., Lin, Y., Chen, Y., Ma, Y., & Wang, T. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1289901 · Cited by 33 · see citing works

Chemical Epigenetics: The Impact of Chemical and Chemical Biology Techniques on Bromodomain Target Validation

Schiedel, M., Moroglu, M., Ascough, D. M. H., Chamberlain, A. E. R., Kamps, J. J. A. G., Sekirnik, A. R., & Conway, S. J. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201812164 · Cited by 34 · see citing works

ARID1A Hypermethylation Disrupts Transcriptional Homeostasis to Promote Squamous Cell Carcinoma Progression

Luo, Q., Wu, X., Chang, W., Zhao, P., Zhu, X., Chen, H., Nan, Y., Luo, A., Zhou, X., Su, D., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-18-2446 · Cited by 34 · see citing works

Diverse Classes of HDAC8 Inhibitors: In Search of Molecular Fingerprints that Regulate Activity

Amin, S. A., Adhikari, N., & Jha, T. (2018) · Future Medicinal Chemistry · doi:10.4155/fmc-2018-0005 · Cited by 33 · see citing works

Targeting epigenetic modifications in cancer therapy: erasing the roadmap to cancer

Mohammad, H. P., Barbash, O., & Creasy, C. L. (2019) · Nature Medicine · doi:10.1038/s41591-019-0376-8 · Cited by 418 · see citing works

Targeting Epigenetics in Cancer

Bennett, R. L., & Licht, J. D. (2017) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010716-105106 · Cited by 252 · see citing works

Epigenetic synthetic lethality approaches in cancer therapy

Yang, H., Cui, W., & Wang, L. (2019) · Clinical Epigenetics · doi:10.1186/s13148-019-0734-x · Cited by 37 · see citing works

Clinical advances in targeting epigenetics for cancer therapy

Feng, S., & Carvalho, D. D. D. (2021) · FEBS Journal · doi:10.1111/febs.15750 · Cited by 107 · see citing works

Targeting epigenetics using synthetic lethality in precision medicine

Chen, E. S. (2018) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-018-2866-0 · Cited by 11 · see citing works